A new tool can predict individualized probability of survival with conservative management (CM) versus dialysis transition ...

Health experts reiterated their call to the public to make “healthier choices” amid the rising number of diabetes cases in ...

Humacyte recently presented positive two-year results from its Phase 3 V007 clinical trial, showing that its acellular tissue engineered vessel (ATEV) provided superior duration of use in high-need ...

Learn how to manage Type 2 diabetes and prevent severe health complications with sustainable lifestyle changes. Get tips on ...

At an international conference, researchers at the forefront of animal-human transplantation compared notes and allowed ...

Chronic kidney disease or CKD, is a condition that builds over time, as a result of inappropriate kidney function. The ...

Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new ...

The Manipal Institute of Nephrology and Urology has now been set up in Kolkata. With state-of-the-art infrastructure and a ...

Humacyte, Inc. ( HUMA) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Good morning, ladies and gentlemen, and welcome to the Humacyte's Third Quarter Results Conference Call. [Operator ...

Remain on track to resubmit the New Drug Application (NDA) for oxylanthanum carbonate (OLC) by year end - Presented new analysis of OLC data at American Society of Nephrology (ASN) which demonstrates ...

Learn how health insurance for young couples and maternity policies ensure financial protection and quality healthcare during ...

With a continued commitment to advancing OLC, we are poised to resubmit the NDA for OLC by the end of the year, following positive discussions ...